Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow

Turk Kardiyoloji Dernegi Arsivi

Volumn 38, Issue 4, 2010, Pages 244-249

  Akçay, Ahmet ^a   Acar, Gürkan ^a   Kurutaş, Ergül ^a   Sökmen, Abdullah ^a   Atli, Yalçin ^a   Nacar, Alper Buǧra ^a   Tuncer, Cemal ^a  

^a NONE

Author keywords

Adrenergic beta antagonists; Blood flow velocity; Coronary circulation; Lipid peroxidation; Nitric oxide; Oxidative stress

Indexed keywords

LIPID; MALONALDEHYDE; NEBIVOLOL; NITRIC OXIDE; SUPEROXIDE DISMUTASE;

ADULT; ANGIOCARDIOGRAPHY; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD CLOT LYSIS; BLOOD PRESSURE; BODY MASS; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY CIRCUMFLEX BRANCH; DRUG DOSE REDUCTION; ERYTHROCYTE; FEMALE; HEART INFARCTION; HEART RATE; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; OXIDATIVE STRESS; SMOKING;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; BENZOPYRANS; BLOOD FLOW VELOCITY; CASE-CONTROL STUDIES; CATALASE; CORONARY CIRCULATION; ERYTHROCYTES; ETHANOLAMINES; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE; NO-REFLOW PHENOMENON; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; VASODILATOR AGENTS;

EID: 79953275789     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Tambe AA, Demany MA, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries-a new angiographic finding. Am Heart J 1972;84:66-71.
2. Kaski JC, Tousoulis D, Galassi AR, McFadden E, Pereira WI, Crea F, et al. Epicardial coronary artery tone and reactivity in patients with normal coronary arteriograms and reduced coronary flow reserve (syndrome X). J Am Coll Cardiol 1991;18:50-4.
3. Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation 1986;74:964-72.
4. Tanriverdi H, Evrengül H, Kuru O, Tanriverdi S, Seleci D, Enli Y, et al. Cigarette smoking-induced oxidative stress may impair endothelial function and coronary blood flow in angiographically normal coronary arteries. Circ J 2006;70:593-9.
5. Sezgin AT, Siǧirci A, Barutçu İ, Topal E, Sezgin N, Özdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis 2003; 14:155-61. (Pubitemid 36543418)
6. Yaymaci B, Daǧdelen S, Bozbuǧa N, Demirkol O, Say B, Güzelmeriç F, et al. The response of the myocardial metabolism to atrial pacing in patients with coronary slow flow. Int J Cardiol 2001;78:151-6. (Pubitemid 32391347)
7. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-478. (Pubitemid 39302636)
8. Li JJ, Qin XW, Li ZC, Zeng HS, Gao Z, Xu B, et al. Increased plasma C-reactive protein and interleukin-6 concentrations in patients with slow coronary flow. Clin Chim Acta 2007;385:43-7. (Pubitemid 47374665)
9. Enli Y, Türk M, Akbay R, Evrengül H, Tanriverdi H, Kuru O, et al. Oxidative stress parameters in patients with slow coronary flow. Adv Ther 2008;25:37-44.
10. Draper HH, Hadley M. Malondialdehyde determination as index of lipid peroxidation. Methods Enzymol 1990;186:421-31. (Pubitemid 20279983)
11. Yagi K. Lipid peroxides and human diseases. Chem Phys Lipids 1987;45:337-51. (Pubitemid 17152340)
12. Çelik T, İyisoy A, Kursaklioǧlu H, Kardeşoǧlu E, Kiliç S, Turhan H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006;24:591-6. (Pubitemid 43261924)
13. Strålin P, Karlsson K, Johansson BO, Marklund SL. The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. Arterioscler Thromb Vasc Biol 1995;15:2032-6.
14. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-8. (Pubitemid 33108132)
15. Mason RP. Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens 2006;8(8 Suppl 2):31-8.
16. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004;1:2-16. (Pubitemid 39551565)
17. Dessy C, Saliez J, Ghisdal P, Daneau G, Lobysheva II, Frérart F, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005;112:1198-205. (Pubitemid 41216127)
18. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005;23:589-96. (Pubitemid 40684718)
19. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112:3795-801. (Pubitemid 43739521)
20. Kuroedov A, Cosentino F, Lüscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004;22:155-68. (Pubitemid 39391186)
21. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88. (Pubitemid 26074824)
22. Dodge JT Jr, Brown BG, Bolson EL, Dodge HT. Intrathoracic spatial location of specified coronary segments on the normal human heart. Applications in quantitative arteriography, assessment of regional risk and contraction, and anatomic display. Circulation 1988;78(5 Pt 1):1167-80.
23. Fridovich I. Superoxide radical: an endogenous toxicant. Annu Rev Pharmacol Toxicol 1983;23:239-57. (Pubitemid 13079375)
24. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8. (Pubitemid 9194347)
25. De Bruyne B, Hersbach F, Pijls NH, Bartunek J, Bech JW, Heyndrickx GR, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "normal" coronary angiography. Circulation 2001; 104:2401-6.
26. Cin VG, Pekdemir H, Camsar A, Çiçek D, Akkuş MN, Parmaksiz T, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Jpn Heart J 2003; 44:907-19. (Pubitemid 41518947)
27. Luoma JS, Strålin P, Marklund SL, Hiltunen TP, Särkioja T, Ylä-Herttuala S. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions: colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. Arterioscler Thromb Vasc Biol 1998;18:157-67. (Pubitemid 28277591)
28. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001;104:511-4. (Pubitemid 32738117)
29. de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004;43:148-53. (Pubitemid 38032077)
30. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71.
31. Troost R, Schwedhelm E, Rojczyk S, Tsikas D, Frölich JC. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000; 50:377-9.